Evidence map›Paper›PMID 40670454›Full record

ArticleScientific reports2025

Enhancing pathological feature discrimination in diabetic retinopathy multi-classification with self-paced progressive multi-scale training.

Qiuji Zhou, Yongde Guo, Wenjian Liu, Yifeng Liu, Yanzhen Lin

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Qiuji ZhouFaculty of Data Science, City University of Macau, Macau SAR, China.
Yongde GuoFaculty of Data Science, City University of Macau, Macau SAR, China. wtkuok@cityu.edu.mo.
Wenjian LiuFaculty of Data Science, City University of Macau, Macau SAR, China.
Yifeng LiuFaculty of Innovation Engineering, Macau University of Science and Technology, Macau SAR, China.
Yanzhen LinFaculty of Data Science, City University of Macau, Macau SAR, China.

Funding

Fundo para o Desenvolvimento das Ciências e da Tecnologia No. 0051/2022/AFJ
6 · The paper itself

Abstract

Diabetic retinopathy (DR) is a common diabetes complication that presents significant diagnostic challenges due to its reliance on expert assessment and the subtlety of small lesions. Although deep learning has shown promise, its effectiveness is often limited by low-quality data and small sample sizes. To address these issues, we propose a novel deep learning framework for DR that incorporates self-paced progressive learning, introducing training samples from simple to complex, and randomized multi-scale image reconstruction for enhanced data augmentation and feature extraction. Additionally, ensemble learning with Kullback-Leibler (KL) divergence-based collaborative regularization improves classification consistency. The method's effectiveness is demonstrated through experiments on the integrated APTOS and MESSIDOR-Kaggle dataset, achieving an AUC of 0.9907 in 4-class classification, marking a 2.2% improvement compared to the ResNet-50 baseline. Notably, the framework achieves a recall of 97.65% and precision of 96.54% for the No-DR class, and a recall of 98.55% for the Severe class, with precision exceeding 91% across all categories. Furthermore, superior classification performance on limited data samples, as well as robust localization of subtle lesions via multi-scale progressive learning, has been demonstrated, underscoring the potential of the proposed framework for practical clinical deployment.

Indexed as

Deep LearningDiabetic RetinopathyImage Processing, Computer-AssistedAlgorithmsHumans

Identifiers

PMID40670454
PMCPMC12267427

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.